Apogee Therapeutics, Inc. APGE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$274.62M-33.7% | -$255.84M-40.5% | -$253.67M-73.0% | -$237.67M-101% | -$205.39M-98.3% | ||
| $1.61M+340% | $1.41M+648% | $1.08M— | $731K— | $367K— | ||
| $52.31M+72.8% | $46.28M+98.3% | $41.96M+134% | $35.92M+164% | $30.27M+236% | ||
| -$234.54M-24.7% | -$227.45M-32.9% | -$232.48M-74.5% | -$220.74M-99.6% | -$188.02M-96.2% | ||
| —— | $5.15M+346% | $5.09M+326% | $5.84M+1,102% | $5.12M+975% | ||
| -$227.91M— | -$179.57M— | —— | —— | —— | ||
| $807.04M+1,679% | $396.49M-19.9% | $65.9M— | $46.54M— | $45.36M— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Apogee Therapeutics, Inc. generate?
- Apogee Therapeutics, Inc. (APGE) generated -$234.5M in operating cash flow over the trailing twelve months.
- What is Apogee Therapeutics, Inc.'s free cash flow?
- After $5.1M of capital expenditures, Apogee Therapeutics, Inc.'s free cash flow was -$232.6M over the trailing twelve months, down 35.0% year over year.
- Where does Apogee Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.